balloon pulmonary angioplasty (BPA) was introduced, which had similarly beneficial effects on hemodynamics, exercise tolerance, and prognosis in patients with inoperable or surgically inaccessible disease. 7-12 In spite of the progress in therapeutic options, some patients who have undergone PEA or BPA still had residual symptoms. 13,14 Health-related quality of life (HRQOL) measurement is a subjective outcome that represents disease impact on a person's function and wellbeing, and can be altered by disease treatment. 15,16 Beyond objective outcomes such as C hronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease characterized by fibrothrombotic obstructions of the pulmonary arteries (PA), resulting in increased pulmonary vascular resistance (PVR), pulmonary vascular remodeling and eventually leading to right ventricular failure. 1 The primary therapy for CTEPH has been pulmonary endarterectomy (PEA), 2 which contributes to better hemodynamics, oxygenation, exercise capacity, and prognosis. 3,4 CTEPH prognosis had been poor until the development of PEA. 5,6 Subsequently,